Goldman Sachs: GLP-1 Weight-Loss Drugs Could Propel US Economic Growth
Goldman Sachs economist Jan Hatzius claims that increased use of GLP-1 weight-loss drugs like Ozempic could boost US GDP by 1% if 60 million Americans are treated by 2028. Healthcare …
Goldman Sachs: GLP-1 Weight-Loss Drugs Could Propel US Economic Growth Read More